Pharmaceutical - Pharmaceutical, Research

Filter

Current filters:

PharmaceuticalResearch

Popular Filters

1 to 25 of 1934 results

UCB reports positive Phase III results for brivaracetam in epilepsy

UCB reports positive Phase III results for brivaracetam in epilepsy

23-07-2014

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset…

BelgiumBRIVARACETAMEpilepsyNeurologicalPartial-onset seizurePharmaceuticalResearchUCB

Merck strengthens commitment to Chinese growth market

Merck strengthens commitment to Chinese growth market

23-07-2014

Germany’s Merck KGaA, a leading company for high-tech products in the pharmaceutical and chemical sectors,…

ChinaFinancialMerckMerck KGaAPharmaceuticalProductionResearch

Tesamorelin, which reduces abdominal fat in HIV patients, may also reduce fat in liver

22-07-2014

The only drug to receive US Food and Drug Administration approval for reduction of the abdominal fat…

EgriftaEMD SeronoMerck KGaANephrology and HepatologyPharmaceuticalResearchtesamorelinTherapy for HIVUSA

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

Queen's University Belfast researchers' breakthrough leads to new clinical trial in bowel cancer

Queen's University Belfast researchers' breakthrough leads to new clinical trial in bowel cancer

21-07-2014

Cancer Research UK scientists have discovered how two genes – called MEK and MET – cause bowel cancer…

Colorectal cancerOncologyPharmaceuticalResearchUKUniversity Belfast

AstraZeneca reveals designs for new global R&D center and HQ in Cambridge, UK

AstraZeneca reveals designs for new global R&D center and HQ in Cambridge, UK

20-07-2014

Anglo-Swedish pharma major AstraZeneca on Friday revealed designs for its planned network of glass-walled…

AstraZenecaManagementPharmaceuticalResearchUK

Fast growth forecast for dengue vaccine market

Fast growth forecast for dengue vaccine market

18-07-2014

Among the five major pharmaceutical markets (5MM: Brazil, India, Mexico, Singapore and Thailand), Brazil…

Asia-PacificBrazilMarkets & MarketingMexicoPharmaceuticalResearchTropical diseases

Amgen announces positive Phase III results for AMG 416 in kidney disease

Amgen announces positive Phase III results for AMG 416 in kidney disease

18-07-2014

USA-based Amgen, the world's leading independent biotech firm, has said its Phase III study evaluating…

AMG 416AmgenChronic kidney diseaseHyperparathyroidismNephrology and HepatologyPharmaceuticalResearchSecondary hyperparathyroidismUSA

Trametinib and dabrafenib gives overall survival benefit compared to vemurafenib

Trametinib and dabrafenib gives overall survival benefit compared to vemurafenib

17-07-2014

GlaxoSmithKline says that the Independent Data Monitoring Committee (IDMC) has recommended a Phase III…

BRAFdabrafenibGlobalGSKMetastatic cutaneous melanomaOncologyPharmaceuticalResearchtrametinibvemurafenib

Pfizer’s BeneFIX reduces bleeding rates in Ph III study

Pfizer’s BeneFIX reduces bleeding rates in Ph III study

16-07-2014

US pharma giant Pfizer today released positive results of a Phase III study comparing a prophylaxis regimen…

BenefixHaemophiliaHematologyHemophilia BPfizerPharmaceuticalResearchSevere hemophilia BUSA

Targacept trial does not show superiority of TC-1734 over donepezil

Targacept trial does not show superiority of TC-1734 over donepezil

15-07-2014

US-based clinical-stage biopharma company Targacept has announced results from a Phase IIb monotherapy…

Alzheimer's diseaseDonepezilNeurologicalPharmaceuticalResearchTargaceptTC-1734USA

Novartis collaborates with Banner Alzheimer's Inst on AD prevention study

Novartis collaborates with Banner Alzheimer's Inst on AD prevention study

15-07-2014

Swiss pharma major Novartis has set up a collaboration with US not-for-profit group the Banner Alzheimer's…

Active immunotherapyAlzheimer's diseaseEuropeNeurologicalNovartisNovartis PharmaceuticalsPharmaceuticalResearchUSA

Research shows OPAT drugs should be first used on inpatients to penetrate the market

Research shows OPAT drugs should be first used on inpatients to penetrate the market

11-07-2014

While more than three quarters of surveyed infectious disease specialists are willing to prescribe Durata’s…

AntibioticsAntibiotics and Infectious diseasesDalvanceDecision Resources GrouporitavancinOritavancinPharmaceuticalResearch

Sanofi Pasteur releases pivotal Ph III results from dengue vaccine study

Sanofi Pasteur releases pivotal Ph III results from dengue vaccine study

11-07-2014

Sanofi Pasteur, the vaccines division of French drug major Sanofi, has announced detailed results of…

FrancePharmaceuticalResearchSanofi PasteurVaccines

inVentiv and ACRES partner to create a global research platform for clinical trials

inVentiv and ACRES partner to create a global research platform for clinical trials

11-07-2014

Two bodies are partnering to fast-track the development of a global system to support responsible conduct…

BiotechnologyClinical researchDrug developmentGlobalGreg KoskiinVentive HealthPharmaceuticalResearch

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

10-07-2014

USA-based Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Japanese…

andexanet alfaCardio-vascularDaiichi SankyoedoxabanJapanLicensingPharmaceuticalPortola PharmaceuticalsResearchSavaysaUSA

A$35 million to advance Australian type 1 juvenile diabetes research

A$35 million to advance Australian type 1 juvenile diabetes research

10-07-2014

Australia’s Minister for Education, Christopher Pyne, and Minister for Health, Peter Dutton, have today…

AustraliaDiabetesFinancialPharmaceuticalResearch

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

10-07-2014

Data published in the New England Journal of Medicine has shown secukinumab to be more effective at treating…

DermatologicalsetanerceptNovartisPharmaceuticalPsoriasisResearchsecukinumabUSA

EMA delays formal adoption of publication of clinical trial data policy

EMA delays formal adoption of publication of clinical trial data policy

10-07-2014

The European Medicines Agency management board has postponed formal adoption of the policy on publication…

EuropeEuropean Medicines AgencyEuropean UnionPharmaceuticalRegulationResearch

1 to 25 of 1934 results

Back to top